[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592408":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":17,"armGroups":26,"interventions":36,"overallOfficials":46,"centralContacts":50,"locations":55,"responsibleParty":74,"collaborators":17,"id":78,"slug":17,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":79,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":17,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":58,"whyStopped":17,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"University of Iowa","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":17},[9,13,15],{"measure":10,"description":11,"timeFrame":12},"Feasibility outcome","Patients with stable SVT are identified in the ED (Threshold \\>90%)","From enrollment to the end of ED encounter (up to 24 hours).",{"measure":10,"description":14,"timeFrame":12},"Eligible participants who provide consent to participate (Threshold \\>50%)",{"measure":10,"description":16,"timeFrame":12},"Participants who complete all study procedures (Threshold \\>80%)",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"RANDOMIZED","SINGLE_GROUP","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":24},"SINGLE",[25],"OUTCOMES_ASSESSOR",[27,32],{"label":28,"type":29,"description":17,"interventionNames":30},"Adenosine","ACTIVE_COMPARATOR",[31],"Drug: adenosine",{"label":33,"type":29,"description":17,"interventionNames":34},"Diltiazem",[35],"Drug: diltiazem",[37,42],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":17},"DRUG","adenosine","IV adenosine at standard doses for SVT (6 mg, 12 mg)",[28],{"type":38,"name":43,"description":44,"armGroupLabels":45,"otherNames":17},"diltiazem","IV diltiazem at standard doses for SVT (0.25 mg\u002Fkg)",[33],[47],{"name":48,"affiliation":5,"role":49},"Anne Zepeski, PharmD","PRINCIPAL_INVESTIGATOR",[51],{"name":48,"role":52,"phone":53,"phoneExt":17,"email":54},"CONTACT","(319) 356-2577","anne-zepeski@uiowa.edu",[56],{"facility":57,"status":58,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"University of Iowa Health Care","RECRUITING","Iowa City","Iowa","52242","United States","US",{"type":65,"coordinates":66},"Point",[67,68],-91.53017,41.66113,{"lat":68,"lon":67},[71],{"name":72,"role":52,"phone":73,"phoneExt":17,"email":54},"Anne Zepeski, PhamD","651-207-9357",{"type":75,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"SPONSOR_INVESTIGATOR","Anne E. Zepeski","Clinical Assistant Professor","100592408",false,"NCT06993038","Adenosine vs Diltiazem for Treatment of SVT in the ED","COMparison of Adenosine Versus Diltiazem FOR Supraventricular Tachycardia in the ED (COMFORT-ED) - Pilot Trial","COMFORT-ED","Inclusion Criteria:\n\n1. Adult patients (18 years and older)\n2. Diagnosis of acute, stable SVT in the emergency department\n\nExclusion Criteria:\n\n1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and\u002For hospital setting).\n2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome\n3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF\\\u003C\u002F= 40%)\n4. Severe bronchoconstrictive lung disease\n5. Prior hypersensitivity to study medication\n6. Previously enrolled in pilot study\n7. Pregnant\n8. Incarcerated","ALL","18 Years","100 Years",{"count":89,"type":90},20,"ESTIMATED","INTERVENTIONAL",[93],"PHASE4","This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.",[96],"Supraventricular Tachycardia (SVT)",[43,39,98],"emergency medicine","2026-05-26",{"date":101,"type":102},"2026-05-28","ACTUAL",{"date":104,"type":102},"2025-08-01",{"date":106,"type":90},"2027-12",{"name":76,"class":6},1]